Maury Raycroft
Stock Analyst at Jefferies
(0.65)
# 3,775
Out of 4,735 analysts
53
Total ratings
20.51%
Success rate
-20.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $1.13 | +165.49% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.99 | +134.11% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.90 | +215.79% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $1.35 | +1,159.26% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $3.08 | +516.88% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $2.91 | +415.46% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $21.66 | +80.06% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $1.21 | +395.87% | 1 | Mar 13, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Upgrades: Buy | $4 → $46 | $11.93 | +285.58% | 1 | Mar 6, 2024 | |
| MGX Metagenomi | Initiates: Buy | $23 | $2.72 | +745.59% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.89 | +1,591.86% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.61 | +44.55% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 → $9 | $1.11 | +710.81% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.61 | +206.51% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $33.70 | -82.20% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $19.76 | +279.55% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $264.99 | -12.45% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.92 | +123.58% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $15.91 | +69.70% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.76 | +184.09% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $11.21 | +328.19% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $4.71 | +664.33% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $3.26 | +3,120.86% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $41.51 | +314.36% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.84 | +446.88% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.24 | +1,998.21% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $1.14 | +3,408.77% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $6.33 | +3,533.49% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $9.94 | +322.54% | 3 | Nov 1, 2017 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $1.13
Upside: +165.49%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.99
Upside: +134.11%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.90
Upside: +215.79%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $1.35
Upside: +1,159.26%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $3.08
Upside: +516.88%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $2.91
Upside: +415.46%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $21.66
Upside: +80.06%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.21
Upside: +395.87%
Corbus Pharmaceuticals Holdings
Mar 6, 2024
Upgrades: Buy
Price Target: $4 → $46
Current: $11.93
Upside: +285.58%
Metagenomi
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $2.72
Upside: +745.59%
Feb 8, 2024
Initiates: Buy
Price Target: $15
Current: $0.89
Upside: +1,591.86%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.61
Upside: +44.55%
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $1.11
Upside: +710.81%
Jan 31, 2023
Initiates: Buy
Price Target: $8
Current: $2.61
Upside: +206.51%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $33.70
Upside: -82.20%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $19.76
Upside: +279.55%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $264.99
Upside: -12.45%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $4.92
Upside: +123.58%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $15.91
Upside: +69.70%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.76
Upside: +184.09%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $11.21
Upside: +328.19%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $4.71
Upside: +664.33%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $3.26
Upside: +3,120.86%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $41.51
Upside: +314.36%
Mar 31, 2021
Initiates: Buy
Price Target: $21
Current: $3.84
Upside: +446.88%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.24
Upside: +1,998.21%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $1.14
Upside: +3,408.77%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $6.33
Upside: +3,533.49%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $9.94
Upside: +322.54%